Table 3 Clinicopathological characteristics in the considerable hypertrophy and minimal hypertrophy groups by univariate analysis
Characteristics | CH (n = 15) | MH (n = 33) | P |
|---|---|---|---|
Epidemiology | |||
Age | 63 ± 12 | 69 ± 7 | 0.10 |
Sex (male/female) | 11/4 | 24/9 | 0.96 |
HBs-Ag positive (%) | 1/15 (6.7%) | 8/33 (24%) | 0.14 |
HCV-Ab positive (%) | 0/15 (0%) | 1/33 (3%) | 0.49 |
Biochemical factors | |||
WBC (/μL) | 4966 ± 1198 | 6987 ± 2625 | < 0.01 |
Hb (g/dL) | 12.4 ± 1.5 | 13.1 ± 1.0 | 0.07 |
Plt (× 104/μL) | 23.5 ± 7.9 | 24.1 ± 7.5 | 0.81 |
CRP (mg/dL) | 0.9 ± 1.3 | 0.9 ± 1.7 | 0.98 |
PT (%) | 92.1 ± 27.6 | 94.5 ± 15.1 | 0.70 |
Total bilirubin (mg/dL) | 0.98 ± 0.53 | 1.59 ± 0.94 | 0.02 |
AST (IU/L) | 53.7 ± 27.5 | 63.4 ± 57.4 | 0.53 |
ALT (IU/L) | 67.9 ± 51.4 | 84.3 ± 83.3 | 0.48 |
Che (IU/L) | 231.6 ± 53.6 | 250.6 ± 66.9 | 0.33 |
Alb (g/dL) | 3.8 ± 0.5 | 3.9 ± 0.4 | 0.36 |
HbA1c (%) | 5.6 ± 0.9 | 5.5 ± 0.9 | 0.68 |
ICGR15 (%) | 10.6 ± 3.7 | 16.1 ± 3.9 | < 0.01 |
99mTc-GSA scintigraphy | |||
LHL15 | 0.914 ± 0.029 | 0.915 ± 0.074 | 0.95 |
Portal pressure | |||
PVP (cmH2O) before PTPE | 13.2 ± 2.3 | 14.1 ± 3.3 | 0.34 |
PVP (cmH2O) after PTPE | 18.2 ± 1.9 | 20.5 ± 3.7 | 0.03 |
Portal flow volume | |||
IR-pFV (%) on day 1 | 112 ± 90 | 90 ± 81 | 0.40 |
IR-pFV (%) on day 3 | 155 ± 96 | 90 ± 59 | < 0.01 |
IR-pFV (%) on day 5 | 150 ± 108 | 111 ± 96 | 0.22 |
IR-pFV (%) on day 7 | 160 ± 112 | 109 ± 95 | 0.11 |
Histological factors | |||
Fibrosis (f2,3,4) (%) | 1/15 (6.7%) | 14/33 (42.4%) | 0.01 |